Biomarkers predicting the 30-day mortality of patients who underwent elective surgery and were infected with SARS-CoV-2 during the post-operative period: A retrospective study

VASILIKI EPAMEINONDAS GEORGAKOPOULOU1, DIMITRIOS BASOULIS1,2, PANTAZIS M. VOUTSINAS1, CHRYSOVALANTIS V. PAPAGEORGIOU3, IRENE ELIADI1, GEORGIOS KARAMANAKOS1, DEMETRIOS A. SPANDIDOS4, NIKOLAOS MATHIOUDAKIS5, PETROS PAPALEXIS6,7, STAVROS PAPADAKOS8, GEORGE FOTAKOPOULOS9, KYRIAKOS TARANTINOS10 and NIKOLAOS V. SIPSAS1,2

1Department of Infectious Diseases-COVID-19 Unit, Laiko General Hospital; 2Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens; 3Pulmonology Department, Laiko General Hospital, 11527 Athens; 4Laboratory of Clinical Virology, School of Medicine, University of Crete, 71003 Heraklion; 5Renal Transplantation Unit, Laiko General Hospital; 6Unit of Endocrinology, First Department of Internal Medicine, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens; 7Department of Biomedical Sciences, University of West Attica, 12243 Athens; 8Department of Gastroenterology, Laiko General Hospital, National and Kapodistrian University of Athens, 11527 Athens; 9Department of Neurosurgery, General University Hospital of Larisa, 41221 Larisa; 101st Pulmonology Department, Sismanogleio Hospital, 15126 Athens, Greece

Received August 10, 2022; Accepted September 15, 2022

DOI: 10.3892/etm.2022.11629

Abstract. The coronavirus disease 2019 (COVID-19) pandemic is a significant global concern that has had major implications for the healthcare system. Patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) undergoing elective or emergency surgical procedures have a substantial risk of mortality and peri-operative complications. The present study aimed to describe the characteristics of patients who underwent elective surgery and developed nosocomial SARS-CoV-2 infection post-surgery. Patients who underwent thoracic, upper and lower abdominal or peripheral elective surgery with a polymerase chain reaction diagnosis of COVID-19, at 3-7 days after the surgery, were enrolled in the present retrospective study. Demographics, vaccination status against SARS-CoV-2, Charlson comorbidity index (CCI) and laboratory data were recorded upon admission to the hospital unit. In total, 116 subjects (80 males, 36 females; mean age, 67.31±16.83 years) fulfilling the inclusion criteria were identified. Among the 116 participants, 14 (12.1%) were intubated. From the 116 individuals analyzed, 84 were alive after 30 days (survivors), and 32 had succumbed to the disease (non-survivors). The mortality rate was 27.6% (32/116). The non-survivors had an older age and a higher CCI score. At the evaluation upon admission to the hospital unit, the survivors presented with higher serum albumin levels and a higher number of blood lymphocytes. In addition, the survivors exhibited lower levels of lactate dehydrogenase, aspartate aminotransferase, alkaline phosphatase (ALP) and C-reactive protein (CRP), as well as a higher neutrophil to lymphocyte ratio (NLR) and CRP to albumin ratio (CAR) (P<0.05). The patients that were intubated had higher levels of gamma glutamyl-transferase (GGT), ALP and ferritin, as well as a higher NLR and platelet to lymphocyte ratio upon admission to the hospital unit (P<0.05). According to the Cox proportional hazards multivariate regression analysis, the only independent predictors of mortality and intubation were ALP and GGT upon admission, respectively (P<0.05). On the whole, the findings of the present study suggest that more stringent guidelines are required in order to prevent infection during the post-operative period.

Introduction

The coronavirus disease 2019 (COVID-19) pandemic is a major global concern that has had significant implications for the healthcare system (1). Elective surgeries have been canceled or postponed in certain hospitals worldwide, and the threshold for emergency surgery has been increased (2).

While surgical delays were frequently caused by hospital capacity and infection transmission concerns, there was also...
ambiguity as regards the peri-operative hazards of individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (3).

It should be noted that COVID-19 infection is linked to significant pulmonary and cardio-circulatory complications, such as respiratory failure, pneumonia, venous thromboembolism, cardiac arrhythmias, or other coagulation issues; thus, a more difficult recovery is anticipated, particularly after the performance of aggressive surgical procedures (4). As a result, major surgical societies recommended that surgeons deliver surgical care that requires local epidemiological, logistical and patient-related aspects into account. Of note, the guidelines that were created in the initial phase of the pandemic used a pragmatic approach and were based on expert opinions, as limited data were available at that time (5).

Previous studies have reported that patients with severe SARS-CoV-2 infection who underwent elective surgery had a high risk of post-operative mortality and of developing complications (6-8). According to other researchers, SARS-CoV-2-positive patients undergoing emergency surgical procedures had a substantial risk of mortality and of developing peri-operative complications as well (4). Furthermore, in a retrospective cohort study of patients undergoing surgery during the incubation period of SARS-CoV-2 infection, a significant number of patients required admission to intensive care units and had a high mortality rate (9).

However, data on the outcomes of patients undergoing surgery and becoming infected with SARS-CoV-2 during the post-operative period are limited. The present study thus aimed to describe the characteristics of patients who underwent elective surgery and developed nosocomial SARS-CoV-2 infection post-surgery, as well as to identify determinants of mortality and other unfavorable outcomes in these patients.

Patients and methods

Study design. The present study was a single-center retrospective study of patients with COVID-19 admitted to the Department of Infectious Diseases-COVID-19 Unit of Laiko General Hospital, Athens, Greece between September 21, 2020 and April 15, 2022. The study was conducted in line with the Declaration of Helsinki and was approved by the Institutional Review Board of Laiko General Hospital (protocol no. 765/12-2021). Written informed was obtained from the patients for inclusion in the study.

The following criteria were required for inclusion in the study: Patients who underwent thoracic, upper and lower abdominal or peripheral elective surgery with a polymerase chain reaction (PCR) diagnosis of COVID-19, at 3-7 days post-surgery, who had been tested negative during the pre-operative evaluation and were admitted to the Department of Infectious Diseases-COVID-19 Unit on the day of COVID-19 diagnosis. Thoracic surgery included esophagectomy. Upper abdominal surgeries included the open repair of an aortic stent leak, the resection of retroperitoneal sarcoma, gastrectomy, splenectomy, hepatectomy, nephrectomy, pancreatectomy and cholepeptic anastomosis.

Lower abdominal surgeries included segmental colectomy, the surgical repair of ureterorarterial fistula, cystectomy, hysterectomy, umbilical hernia repair, abdominal wall hernia repair, low anterior resection, abdominoperineal resection and renal transplantation. Peripheral surgeries included orthopedic surgeries, such as the repair of knee, hip and metatarsal fractures, and amputations due to limb gangrene.

The patients were classified into the following categories according to the severity of COVID-19 infection: Asymptomatic, mild/moderate, severe and critical, based on the clinical spectrum of SARS-CoV-2 infection (10). All patients were uniformly treated according to the National Institutes of Health (NIH) protocols (10). Some of the participants had a follow-up appointment at 1 month after their admission to the post-COVID-19 outpatient clinic of Laiko General Hospital, and if that was not possible, a telephone call was made to determine the 30-day mortality rate. The exclusion criteria were an age <18 years and a lack of data available on survival at 1 month post-diagnosis.

Investigations. Data regarding demographics, vaccination status against SARS-CoV-2 and the Charlson comorbidity index (CCI) were recorded. Hemoglobin (Hb), white blood cells, blood neutrophils, lymphocytes and immature granulocytes, neutrophil to lymphocyte ratio (NLR), platelets (PLTs), platelet to lymphocyte ratio (PLR), C-reactive protein (CRP), serum albumin, CRP to albumin ratio (CAR), serum lactate dehydrogenase (LDH), d-dimer levels, ferritin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) and gamma glutamyl-transferase (GGT) were recorded upon admission to the Department of Infectious Diseases-COVID-19 Unit. Investigations were evaluated for the implementation of intubation and all-cause mortality at 30 days.

Statistical analysis. Continuous variables are presented as the mean (standard deviation). The assessment of the normal distribution of variables was performed with the use the Kolmogorov-Smirnov test. The comparison of normally distributed variables was performed using an independent samples Student's t-test on variables with two groups and not normally distributed variables were examined using an unpaired non-parametric two-tailed Mann-Whitney test. Categorical variables were examined using the Fischer's exact test or the Chi-squared test and are shown as absolute numbers (frequency, percentage). The CCI data were numerically recorded. To identify predictors of event(s) (event=intubation, or mortality at 30 days), statistically significant differences. Statistical analysis
Results

In total, 116 subjects (80 males, 36 females; mean age, 67.31±16.83 years) fulfilling the inclusion criteria were identified. Among the 116 participants, 14 (12.1%) were intubated. From the 116 individuals examined, 84 were alive after 30 days (survivors), and 32 had succumbed to the disease (non-survivors). The mortality rate was 27.6% (32/116). The Demographics and baseline data of the study population are presented in Table I.

The non-survivors had an older age and a higher CCI score. At the evaluation upon admission to the hospital unit, the survivors presented with higher serum albumin levels and a higher number of blood lymphocytes. In addition, the survivors exhibited lower levels of LDH, AST, ALP, CRP, NLR and CAR (P<0.05; Table II). It was also found that the patients that were intubated had higher levels of GGT, ALP, ferritin, NLR and PLR on admission to the hospital unit (P<0.05; Table III).

All parameters with significant differences in the univariate analysis were analyzed using the Cox proportional hazards multivariate regression analysis. The outcome was all-cause mortality, and cases were censored at 30 days. The results demonstrated that the only independent predictor of mortality was the ALP levels upon admission (P<0.05; Table IV). The ALP levels were found to be significant predictors of mortality, as also shown by ROC curve analysis (Fig. 1). A value of ALP >122.5 U/l predicted mortality with 71.4% sensitivity and 69.6% specificity (AUC, 0.702). Kaplan-Meier survival analysis based on cut-off values for ALP revealed a worse survival for subjects with ALP levels >122.5 U/l (log-rank test for trend, P<0.05; Fig. 2).

Cox proportional hazards multivariate regression analysis with intubation as the outcome identified GGT levels as a significant biomarker for the prediction of intubation (P<0.05; Table V). The GGT levels were also found to be significant predictors of mortality by ROC curve analysis (Fig. 3). A value of GGT >139 U/l predicted intubation with 66.7% sensitivity and 71.6% specificity (AUC, 0.742).

Discussion

According to the results of the present study, the mortality rate of patients who underwent elective surgery and were infected with SARS-CoV-2 during the post-operative period was high. In the study by Kader et al (11), the risk of mortality following elective orthopedic surgery was low. On the contrary, in a multicenter retrospective study by Clement et al (12) on mortality and risk factors related to COVID-19 following orthopedic and trauma surgery, the mortality rate of patients infected with SARS-CoV-2 was 32.4%, while in another study by the same researchers on the rate of COVID-19-associated mortality following elective hip and knee arthroplasty, the mortality rate was 20% (13).
Table II. Univariate analysis (outcome, mortality).

| Parameter            | Outcome  | No. of patients | Mean   | SD     | P-value |
|----------------------|----------|-----------------|--------|--------|---------|
| Age, years           | Recovery | 84              | 64.95  | 17.97  | 0.03    |
|                      | Mortality| 32              | 73.50  | 11.48  |         |
| CCI                  | Recovery | 80              | 4.30   | 2.61   | 0.01    |
|                      | Mortality| 36              | 5.94   | 2.37   |         |
| Hb (g/dl)            | Recovery | 80              | 10.40  | 1.63   | 0.97    |
|                      | Mortality| 36              | 10.44  | 1.63   |         |
| WBCs (K/µl)          | Recovery | 84              | 8.99   | 4.26   | 0.20    |
|                      | Mortality| 32              | 10.16  | 4.82   |         |
| IGs (10⁹/l)          | Recovery | 84              | 0.17   | 0.24   | 0.80    |
|                      | Mortality| 32              | 0.18   | 0.19   |         |
| Lymphocytes (K/µl)   | Recovery | 84              | 1.10   | 0.58   | 0.04    |
|                      | Mortality| 32              | 0.86   | 0.57   |         |
| Neutrophils (K/µl)   | Recovery | 84              | 7.08   | 3.97   | 0.06    |
|                      | Mortality| 32              | 8.75   | 4.56   |         |
| PLTs (K/µl)          | Recovery | 84              | 396.52 | 420.25 | 0.10    |
|                      | Mortality| 30              | 269.60 | 111.01 |         |
| Fibrinogen (mg/dl)   | Recovery | 64              | 561.00 | 160.48 | 0.10    |
|                      | Mortality| 30              | 499.13 | 184.99 |         |
| Albumin (g/l)        | Recovery | 82              | 32.55  | 5.00   | 0.01    |
|                      | Mortality| 32              | 28.00  | 5.82   |         |
| GGT (U/l)            | Recovery | 82              | 135.76 | 194.38 | 0.26    |
|                      | Mortality| 32              | 182.00 | 203.80 |         |
| LDH (U/l)            | Recovery | 84              | 266.26 | 105.29 | 0.01    |
|                      | Mortality| 32              | 397.75 | 287.10 |         |
| ALT (U/l)            | Recovery | 84              | 36.76  | 31.76  | 0.21    |
|                      | Mortality| 30              | 81.20  | 191.30 |         |
| d-Dimers (µg/ml)     | Recovery | 56              | 3.32   | 2.74   | 0.92    |
|                      | Mortality| 30              | 3.80   | 3.29   |         |
| Creatinine (mg/dl)   | Recovery | 80              | 1.14   | 0.80   | 0.54    |
|                      | Mortality| 36              | 1.42   | 1.41   |         |
| AST (U/l)            | Recovery | 80              | 35.48  | 27.46  | 0.03    |
|                      | Mortality| 36              | 150.44 | 284.95 |         |
| ALP (U/l)            | Recovery | 80              | 118.02 | 90.68  | 0.005   |
|                      | Mortality| 36              | 181.77 | 149.97 |         |
| Ferritin (ng/ml)     | Recovery | 66              | 733.74 | 559.13 | 0.06    |
|                      | Mortality| 32              | 1367.28| 1917.45|         |
| CRP (mg/l)           | Recovery | 78              | 74.74  | 58.34  | 0.003   |
|                      | Mortality| 36              | 131.87 | 110.36 |         |
| NLR                  | Recovery | 80              | 10.16  | 17.31  | 0.01    |
|                      | Mortality| 36              | 14.56  | 11.43  |         |
| PLR                  | Recovery | 80              | 517.53 | 872.83 | 0.33    |
|                      | Mortality| 34              | 439.11 | 287.33 |         |
| CAR                  | Recovery | 76              | 2.40   | 2.03   | 0.004   |
|                      | Mortality| 36              | 5.44   | 5.58   |         |
| Sex                  |           |                 |        |        | 0.61    |
| Female               | Recovery | 26              |        |        |         |
|                      | Mortality| 10              |        |        |         |
| Male                 | Recovery | 54              |        |        |         |
|                      | Mortality| 26              |        |        |         |
| Type of surgery      |           |                 |        |        | 0.15    |
| Thoracic             | Recovery | 6               |        |        |         |
|                      | Mortality| 4               |        |        |         |
In their study on the clinical outcomes of patients with COVID-19 following thoracic surgery, Al Masri et al (14) reported that the mortality rate was 25%. In that same study, fatal outcomes were associated with decreased levels of serum albumin, and an open surgical procedure, the oxygen desaturation at the time of the COVID-19 diagnosis, and a PCR cycle threshold (Ct) value <20 were related to mortality (14). Furthermore, in their study on patients who underwent cardiac surgery and were then incidentally detected with COVID-19 post-surgery, Uysal et al (15)
| Parameter           | Outcome       | No. of patients | Mean   | SD     | P-value |
|---------------------|---------------|-----------------|--------|--------|---------|
| Age, years          | Non-intubated | 102             | 67.16  | 17.34  | 0.79    |
|                     | Intubated     | 14              | 68.43  | 12.97  |         |
| CCI                 | Non-intubated | 102             | 4.73   | 2.61   | 0.57    |
|                     | Intubated     | 14              | 5.43   | 2.92   |         |
| Hb (g/dl)           | Non-intubated | 102             | 10.43  | 1.62   | 0.83    |
|                     | Intubated     | 14              | 10.31  | 1.70   |         |
| WBCS (K/µl)         | Non-intubated | 102             | 9.33   | 4.41   | 0.91    |
|                     | Intubated     | 14              | 9.19   | 4.78   |         |
| IGs (10^9/l)        | Non-intubated | 102             | 0.17   | 0.24   | 0.75    |
|                     | Intubated     | 14              | 0.15   | 0.14   |         |
| Lymphocytes (K/µl)  | Non-intubated | 102             | 1.07   | 0.58   | 0.07    |
|                     | Intubated     | 14              | 0.78   | 0.54   |         |
| Neutrophils (K/µl)  | Non-intubated | 102             | 7.48   | 4.18   | 0.69    |
|                     | Intubated     | 14              | 8.00   | 4.37   |         |
| PLTs (K/µl)         | Non-intubated | 100             | 369.34 | 392.23 | 0.63    |
|                     | Intubated     | 14              | 318.71 | 91.4   |         |
| Fibrinogen (mg/dl)  | Non-intubated | 80              | 541.37 | 173.04 | 0.98    |
|                     | Intubated     | 14              | 540.57 | 158.73 |         |
| Albumin (g/l)       | Non-intubated | 100             | 31.64  | 5.45   | 0.06    |
|                     | Intubated     | 14              | 28.65  | 6.20   |         |
| GGT (U/l)           | Non-intubated | 102             | 130.04 | 179.00 | 0.04    |
|                     | Intubated     | 12              | 307.67 | 273.40 |         |
| LDH (U/l)           | Non-intubated | 102             | 300.14 | 190.32 | 0.70    |
|                     | Intubated     | 14              | 320.00 | 127.92 |         |
| ALT (U/l)           | Non-intubated | 100             | 51.56  | 108.86 | 0.39    |
|                     | Intubated     | 14              | 26.28  | 24.13  |         |
| d-Dimers (µg/ml)    | Non-intubated | 72              | 3.53   | 3.14   | 0.40    |
|                     | Intubated     | 14              | 3.24   | 1.54   |         |
| Creatinine (mg/dl)  | Non-intubated | 102             | 1.21   | 1.05   | 0.48    |
|                     | Intubated     | 14              | 1.34   | 0.89   |         |
| AST (U/l)           | Non-intubated | 102             | 70.80  | 174.49 | 0.90    |
|                     | Intubated     | 14              | 73.71  | 108.91 |         |
| ALP (U/l)           | Non-intubated | 102             | 134.27 | 119.99 | 0.015   |
|                     | Intubated     | 14              | 163.57 | 74.89  |         |
| Ferritin (ng/ml)    | Non-intubated | 84              | 770.47 | 655.04 | 0.015   |
|                     | Intubated     | 14              | 1961.42| 2635.74|         |
| CRP (mg/l)          | Non-intubated | 100             | 89.84  | 80.17  | 0.46    |
|                     | Intubated     | 14              | 113.80 | 98.18  |         |
| NLR                 | Non-intubated | 102             | 11.00  | 16.30  | 0.02    |
|                     | Intubated     | 14              | 15.36  | 11.36  |         |
| PLR                 | Non-intubated | 100             | 482.76 | 791.23 | 0.008   |
|                     | Intubated     | 14              | 575.44 | 273.55 |         |
| CAR                 | Non-intubated | 98              | 3.21   | 3.62   | 0.47    |
|                     | Intubated     | 14              | 4.53   | 5.04   |         |
| Sex                 |               |                 |        |        | 0.90    |
| Female              | Non-intubated | 32              |        |        |         |
|                     | Intubated     | 4               |        |        |         |
| Male                | Non-intubated | 70              |        |        |         |
|                     | Intubated     | 10              |        |        |         |
| Type of surgery     |               |                 |        |        | 0.46    |
| Thoracic            | Non-intubated | 8               |        |        |         |
|                     | Intubated     | 2               |        |        |         |
reported a mortality rate of 20.7%, while in that same study, increased neutrophil and decreased lymphocyte counts were associated with poor outcomes.

Tabourin et al. (16), in a post-operative assessment of the nosocomial transmission of COVID-19 following robotic surgery for urinary and gynecological cancer, as well as Bacalbasa et al. (17) in a post-operative assessment of the nosocomial transmission of COVID-19 following surgery for ovarian cancer, found low mortality rates. Of note, the present study did not include patients who underwent robot-assisted surgery or surgery for ovarian cancer.

Prasad et al. (18), in their study on patients who underwent different types of elective surgery who tested positive for COVID-19 post-surgery, reported increased complications, providing no data however, on the predictors of intubation and mortality. To the best of our knowledge, the present study is the first to report data on the predictors of poor outcomes of patients who underwent several different types of surgery and were infected with SARS-CoV-2 during the post-operative period.

Of note, association was found between the type of surgery and poor outcomes. It is known that thoracic and abdominal surgery are more frequently related to adverse events and pulmonary complications in particular (19).

In the present study, liver biomarkers were associated with patient outcomes. It is known that SARS-CoV-2 is a...
systemic infection that affects numerous organs, including the kidneys, pancreas, liver and heart (20‑23). Liver impairment is present in more than half of individuals infected with SARS‑CoV‑2, and this impairment becomes more severe as the disease progresses. Moreover, SARS‑CoV‑2 RNA has been observed in the blood and hepatocytes of infected patients. The high density of ACE2 receptors on cholangiocytes and bile duct cells of the liver, and bile duct cells of the liver apparently facilitates the access of SARS‑CoV‑2 to the cells where they proliferate, resulting in the disruption of liver function (24). Additionally, there is evidence to support the hypothesis that the majority of viruses that attack the respiratory system can injure liver cells via the CD8⁺‑mediated immune response (24). Moreover, liver enzymes have been shown to be associated with poor outcomes of patients with COVID‑19 (25‑28). To the best of our knowledge, the present study is the first to report GGT and ALP as biomarkers predicting poor outcomes of patients who underwent elective surgery.

The present study has certain limitations. The present study had a retrospective design, and there no control group was included. Furthermore, it is possible that the negative results obtained in the present study (all‑cause mortality) are attributable to other etiologies in addition to severe COVID‑19 (thromboembolism, sepsis, or coexisting diseases). In addition, another important limitation is the heterogeneity of the cohort, which underwent lower and upper gastrointestinal surgery or other complex procedures. Finally, the present study did not include patients who underwent other types of surgery, such as neurosurgery or robot‑assisted laparoscopy surgery.

The advantages of the present study however, are the relatively large number of patients who underwent surgery, as well as the fact that the participants were patients who underwent several different types of surgery. Other additional strong points of the study are the reliable follow‑up and the availability of 30‑day data.

In conclusion, in the present retrospective study, mortality occurred in 27.6% of the patients who underwent elective surgery and who were infected with COVID‑19 post‑operatively. AUC, 0.742. GGT, gamma glutamyl‑transferase; AUC, area under the curve.

### Table V. Cox regression multivariable analysis (outcome, intubation).

| Parameter     | P‑value | Exp(B) | Lower | Upper |
|---------------|---------|--------|-------|-------|
| NLR           | 0.209   | 1.060  | 0.968 | 1.162 |
| PLR           | 0.278   | 0.999  | 0.997 | 1.001 |
| GGT (U/l)     | 0.015   | 1.006  | 1.001 | 1.012 |
| Ferritin (ng/ml) | 0.736   | 1.000  | 0.990 | 0.999 |
| ALP (U/l)     | 0.294   | 0.994  | 0.982 | 1.005 |

ALP, alkaline phosphatase; GGT, gamma glutamyl‑transferase; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio.

**Acknowledgements**

Not applicable.

**Funding**

No funding was received.
Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

KT, GF and VEG conceptualized the study. VEG, DB, PMV, GK, IE, SP and CVP advised on patient care and medical treatment, were involved in data analysis and wrote and prepared the draft of the manuscript. NM, KT, DAS, PP, GF and NVS analyzed the data and provided critical revisions. VEG and NVS confirm the authenticity of all the data. All authors contributed to manuscript revision and have read and approved the final version of the manuscript.

Ethics approval and consent to participate

The present study was conducted in line with the Declaration of Helsinki and was approved by the Institutional Review Board of Laiko General Hospital (protocol no. 765/12/2021). Written informed consent was obtained from the patients prior to the study. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Patient consent for publication

Not applicable.

Competing interests

DAS is the Editor-in-Chief for the journal, but had no personal involvement in the reviewing process, or any influence in terms of adjudicating on the final decision, for this article. The other authors declare that they have no competing interests.

References

1. Axiotakis LG Jr, Youngerman BE, Casals RK, Cooke TS, Winston GM, Chang CL, Boyett DM, Lalwani AK and McKann GM: Risk of acquiring perioperative COVID-19 during the initial pandemic peak: A retrospective cohort study. Ann Surg 273: 41-48, 2021.

2. COVIDSurg Collaborative: Elective surgery cancellations due to the COVID-19 pandemic: Global predictive modelling to inform surgical recovery plans. Br J Surg 107: 1440-1449, 2020.

3. Al‑Jabir A, Kerwan A, Nicola M, Alsafi Z, Khan M, Sohrabi C, O'Neill N, Iosifidis C, Griffin M, Mathew G and Agha R: Impact of the Coronavirus (COVID‑19) pandemic on surgical practice‑Part 1. Int J Surg 79: 168‑179, 2020.

4. Knisely A, Zhou ZN, Wu J, Huang Y, Holcomb K, Melamed A, Advincula AP, Lalwani A, Khoury‑Collado F, Tergas AI, et al: Perioperative morbidity and mortality of patients with COVID‑19 who undergo urgent and emergent surgical procedures. Ann Surg 273: 34‑40, 2021.

5. Heffernan DS, Evans HL, Huston JM, Claridge JA, Blake DP, May AK, Beilman GS, Barrie PS and Kaplan LJ: Surgical infection society guidance for operative and peri‑operative care of adult patients infected by the severe acute respiratory syndrome coronavirus‑2 (SARS‑CoV‑2). Surg Infect (Larchmt) 21: 301‑308, 2020.

6. COVIDSurg Collaborative: Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS‑CoV‑2 infection: An international cohort study. Lancet 396: 27‑38, 2020.

7. Jonker PKC, van der Plas WY, Steinkamp PJ, Poelstra R, Emous M, van der Meij W, Thunnissen F, Bierman WFW, Struys MMRF, de Reuver PR, et al: Perioperative SARS‑CoV‑2 infections increase mortality, pulmonary complications, and thromboembolic event rates: A Dutch, multicenter, matched‑cohort clinical study. Surgery 169: 264‑274, 2021.

8. Doglietto F, Vezzoli M, Gheza F, Lussardi GL, Domenicucci M, Vecchiarelli L, Zanin L, Saraceno G, Signorini L, Panciani PP, et al: Factors associated with surgical mortality and complications among patients with and without coronavirus disease 2019 (COVID‑19) in Italy. JAMA Surg 155: 691‑702, 2020.

9. Lei S, Jiang F, Su W, Chen C, Chen J, Mei W, Zhan LY, Jia Y, Zhang L, Liu D, et al: Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID‑19 infection. ClinicalMedicine 21: 100331, 2021.

10. COVID‑19 Treatment Guidelines Panel: Coronavirus Disease 2019 (COVID‑19) Treatment Guidelines. National Institutes of Health, Bethesda, MD, 2021. https://www.covid19treatmentguidelines.nih.gov/. Accessed October 10, 2021.

11. Kader N, Clement ND, Patel V, Caplan N, Banaszkiewicz P and Kader D: The theoretical mortality risk of an asymptomatic patient with a negative SARS‑CoV‑2 test developing COVID‑19 following elective orthopaedic surgery. Bone Joint J 102‑B: 1256‑1260, 2020.

12. Clement ND, Hall AJ, Makaram NS, Robinson PG, Patton RFL, Moran M, Macpherson GJ, Duckworth AD and Jenkins PJ: IMPACT‑Restart: The influence of COVID‑19 on postoperative mortality and risk factors associated with SARS‑CoV‑2 infection after orthopaedic and trauma surgery. Bone Joint J 102‑B: 1774‑1781, 2020.

13. Clement ND, Hall AJ, Kader N: IMPACT Restart Collaboration, Ollivere B, Oudseides K, Kader DF, Deehan DJ and Duckworth AD: The rate of COVID‑19 and associated mortality after elective hip and knee arthroplasty prior to cessation of elective services in UK. Bone Joint J 103‑B: 681‑688, 2021.

14. Al Masri E, Redwan B, Thiel B, Ellger B, Begher C, Biancosino C and Kösek V: Clinical outcome in patients with nosocomial COVID‑19 infection after thoracic surgery. Adv Exp Med Biol 1374: 33‑40, 2022.

15. Uysal A, Ertürk E, Abacilar AF, Duman U and Dogan OF: The outcomes of patients incidentally confirmed with Covid‑19 after cardiac surgery. Heart Surg Forum 24: E940‑E946, 2021.

16. Tabourin T, Sarfati J, Pinar U, Beaud N, Parra J, Vaessen C, Gomez F, Benamran D, Canlorbe G, Belghiti J, et al: Postoperative assessment of nosocomial transmission of COVID‑19 after robotic surgical procedures during the pandemic. Urol Oncol 39: 298‑e11, 2021.

17. Bicalbas N and Balescu I: The Impact of COVID‑19 infection during the postoperative period after surgery for ovarian cancer. In Vivo 36: 1337‑1341, 2022.

18. Prasad NK, Lake R, Englum BR, Turner DJ, Siddiqui T, Mayorga‑Carlin M, Sorkin JD and Lal BK: Increased complications in patients who test COVID‑19 positive after elective surgery and implications for pre and postoperative screening. Am J Surg 223: 380‑387, 2022.

19. Canet J, Gallart L, Gomar C, Paluzie G, Vallès J, Castillo J, Karamichalos P, Papalexis P, Asimakopoulou S, Chlapoutakis S, Pierrakou A, Makrodimitri S, Sypsa G, Apostolou A, Eliadi I, Makrodimitri S, Spandidos DA, Mathioudakis N, Papageorgiou CV , Barlampa D, Garmpi A, Chiapoutakis S, Sabaté S, Mazo V , Briones Z and Sanchis J; ARISCAT Group: Prediction of postoperative pulmonary complications in a population‑based surgical cohort. Anaesthesiology 113: 1338‑1350, 2010.

20. Georgakopoulou VE, Gkoufa A, Damaskos C, Garmpi A, Venetikou MS, Paramythiotis D, Papageorgiou CV, de Reuver PR, Struys MMRF, de Reuver PR, et al: COVID‑19‑associated organizing pneumonia responding well to corticosteroids: A report of two cases and a review of the literature. Exp Ther Med 24: 368, 2022.

21. Georgakopoulou VE, Gkoufa A, Damaskos C, Garmpi A, Venetikou MS, Paramythiotis D, Papageorgiou CV, de Reuver PR, Struys MMRF, de Reuver PR, et al: COVID‑19‑associated organizing pneumonia responding well to corticosteroids: A report of two cases and a review of the literature. Exp Ther Med 24: 368, 2022.
24. Bzeizi K, Abdulla M, Mohammed N, Alqamish J, Jamshidi N and Broering D: Effect of COVID-19 on liver abnormalities: A systematic review and meta-analysis. Sci Rep 11: 10599, 2021.

25. Krishnan A, Prichett L, Tao X, Alqahtani SA, Hamilton JP, Mezey E, Strauss AT, Kim A, Potter JI, Chen PH and Woreta TA: Abnormal liver chemistries as a predictor of COVID-19 severity and clinical outcomes in hospitalized patients. World J Gastroenterol 28: 570-587, 2022.

26. Del Zompo F, De Siena M, Ianiro G, Gasbarrini A, Pompili M and Ponziani FR: Prevalence of liver injury and correlation with clinical outcomes in patients with COVID-19: Systematic review with meta-analysis. Eur Rev Med Pharmacol Sci 24: 13072-13088, 2020.

27. Liu J, Yu C, Yang Q, Yuan X, Yang F, Li P, Chen G, Liang W and Yang Y: The clinical implication of gamma-glutamyl transpeptidase in COVID-19. Liver Res 5: 209-216, 2021.

28. Cholongitas E, Bali T, Georgakopoulou VE, Giannakodimos A, Gyftopoulos A, Georgilaki V, Gerogiannis D, Basoulis D, Efialt I, Karamanakos G, et al: Prevalence of abnormal liver biochemistry and its impact on COVID-19 patients’ outcomes: A single-center Greek study. Ann Gastroenterol 35: 290-296, 2022.